Precision Therapeutics® Selects OpenClinica Electronic Data Capture for Cancer Clinical Trials

Precision says OpenClinica is the most powerful and beneficial EDC solution on the market.

Waltham, MA and Pittsburgh, PA (PRWEB) January 11, 2011

Precision Therapeutics, a leader in the science of cancer therapy, has selected OpenClinica Enterprise technology from Akaza Research to provide electronic data capture and clinical data management capabilities for its clinical trials. Precision says Akaza's OpenClinica is the most powerful and beneficial solution on the market.

"In our evaluation of a number of products we found the OpenClinica Enterprise solution provided the best combination of capabilities, support and cost effectiveness for our trials," said Dr. Holly Gallion, Precision's Vice President of Clinical Affairs. "We operate a high-performance group that needs to make sure they are maximizing productivity and quality in their clinical trial activities." Based in Pittsburgh, Precision Therapeutics improves the outcomes of cancer patients by providing personalized medicine solutions that aim to increase quality of life and cancer survival rates.

Produced by Akaza Research of Waltham, MA, OpenClinica is open source software for electronic data capture (EDC) and clinical data management (CDM). OpenClinica is used by hundreds of leading clinical research groups worldwide, both large and small, across numerous therapeutic areas.

The OpenClinica Enterprise Edition provides clinical researchers with a certified, regulatory-compliant, commercially supported e-clinical infrastructure for mission critical settings. It offers enhanced performance and security, guaranteed professional-grade support and support for validation and regulatory compliance.

"We are enthusiastic about bringing the OpenClinica Enterprise solution to Precision Therapeutics," said Jeff Halperin, Director of Client Services at Akaza Research. "Increased transparency into clinical trial progress and more rapid access to higher quality clinical trial data are just a few of the numerous benefits we will work with Precision to realize."

About Precision Therapeutics

Founded in 1995, Precision Therapeutics is committed to improving outcomes of cancer patients. As leaders in the science of individualizing cancer therapy through the use of a proprietary and unique live-tissue platform, Precision develops novel markers to help guide treatment decisions based on the biological processes of each individual's cancer. Precision's state-of-the-art bioinformatics combined with the analysis of the live molecular, proteomic and genomic activity of each patient's cancer offers an innovative foundation to further the development of predictive markers for cancer therapy. Precision's first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician with the goal of optimizing patient outcomes.

About OpenClinica®

OpenClinica is open source, web-based clinical trials software for electronic data capture (EDC) and clinical data management (CDM). OpenClinica facilitates study protocol configuration, data collection via electronic case report forms (eCRFs), and enables productive clinical trials management. OpenClinica supports HIPAA, 21 CFR Part 11, and other regulatory guidelines and is designed as a standards-based, extensible, and modular platform. The OpenClinica Community (free) and Enterprise (commercial) Editions provide a dramatically lower cost of ownership when compared with alternative proprietary technologies. For more information (including product downloads) visit or follow @OpenClinica on Twitter.

About Akaza Research®

Akaza Research is the provider of the leading open source clinical trial software, OpenClinica. Trusted by hundreds of biopharmaceutical companies, contract research organizations, academic, and government organizations worldwide, Akaza's professional open source model brings Open Source Software (OSS) into the mainstream of today's clinical research enterprise. The company provides commercial support to its OpenClinica customers across six continents servicing clinical studies of all types and sizes. For more information, visit